Cancer Genetics — Q3 2017 Earnings Presentation
13 slides from Cancer Genetics's earnings presentation, Nov 9, 2017
Slide 1: Forward-Looking Statements
Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical develo
Slide 2: Everything we do is focused on 1 key idea
Everything we do is focused on 1 KEY idea .. deliver innovation & patient value by providing the most comprehensive capabilities For precision oncology development.
Slide 3: Revenue & Growth Highlights
Q3 Revenue Amounts in $ millions Revenue & Growth Highlights p.4 4-Year CAGR 52% $8.0M 4-Year CAGR 42% Full year Revenue Amounts in $ millions $6.6M $10.2M $18.0M $27M 2013 2014 2015 2016 $1.5M $4.2M $7.0M Q3 2014 Q3 2015 Q3 2016 Q3 2017
Slide 4: Revenue & Operating Expenses
Revenue & Operating Expenses Amounts in $ millions Driving Operational Efficiency and a Clear Path to Profitability Response Acquisition Operating expenses decreased by $2.3 million for the first 9 months of 2017 over the same period in 2016 based on streamlining operations. ~$200k of G&A expense in
Slide 5: Revenues By Market & Customer Category
Revenues By Market & Customer Category Biopharma Services Supports over 190 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 52 for immuno-oncology indications. $4.2M Clinical Services 11% increase in test count, driving a 7% increase in clinical revenue over Q3 2016 d
Slide 6: Q3 2017 Financial Highlights
Q3 2017 Financial Highlights Revenues of $8.0 million, 19% increase over $6.8 million in Q3 2016. Biopharma Services increased 10%; Clinical Services increased by 7%; and Discovery Services grew 280% year-over-year. Total Operating Expenses were $6.6 million, an increase of 4% from $6.3 million duri
Slide 7: Q3 2017 Business Highlights
Q3 2017 Business Highlights Frost & Sullivan acclaimed CGI’s advanced genomic & biomarker technologies that drive industry innovation in support of precision cancer treatment. Presented at 2017 Disruptive Growth Company Showcase, The MicroCap Conference, and hosted panel discussion on “The Convergen
Slide 8: Income Statement Items
Income Statement Items ($ in Thousands) Q3 2016 Q3 2017 9 mos 2016 9 mos 2017 Revenue $6,750 $8,028 $19,819 $21,598 Gross Profit $2,306 $3,440 $6,987 $8,767 Gross Margin (%) 34% 43% 35% 41% Research & Development (R&D) $1,594 $981 $4,806 $3,080 Sales & Marketing (S&M) $1,054 $1,301 $3,731 $3,437 Gen
Slide 9: Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress
Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress Biopharma bookings to billing ratio of 1.6 on $8.2M of Q3 2017 bookings Record quarterly biopharma bookings of $8.2M, up 134% year over year expected to drive future revenue increases 59% increase in biopharma projects from 12
Slide 10: Industry Leading Capabilities in Expanding Field of Immuno-Oncology
Confirm Expressed Somatic Mutations NGS: Whole Transcriptome Confirm by Sanger NGS: Exome / Oncology Panel Identify Somatic Mutations TMB & MSI HLA Type Epitope Prediction Immune Repertoire (PMBCs) Pathology Histology Neoantigen Validation KEY: DNA Analysis RNA Analysis Bioinformatic Analysis Indust
Slide 11: 2017 Goals
2017 Goals Multiple Myeloma NGS Panel [Mayo] Further Expansion in Asia-Pacific Integration of vivoPharm Launch IO capabilities for Drug Discovery & Repurposing Develop Genetic Counselor Network Expand Hereditary Service Offering Liquid Biopsy for Kidney Cancer Bioinformatics Center of Excellence in
Slide 12: CGI Headquarters and Office Locations
www.cgix.com www.cancergenetics.com CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 RUTHERFORD, NJ, USA #3-1-135/1A CNR Complex Mallapur Main Road, R.R. Dst. Hyderabad – 500 076, Telangana Phone: +91 040-2717-8178 HYDERABAD, INDIA Research Triangle Park 133 Southcente
Slide 13: = if pnd
= if pnd J INCORPORATED asoag WWW CANCERGENETICS.COM